![]() |
市场调查报告书
商品编码
1500219
重组细胞培养补充品市场:按产品、来源、应用和最终用途 - 2024-2030 年全球预测Recombinant Cell Culture Supplements Market by Product (Recombinant Albumin, Recombinant Aprotinin, Recombinant Growth Factors), Source (Animals, Human), Application, End-use - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
重组细胞培养补充品市场规模预计 2023 年为 6.8877 亿美元,2024 年达到 7.8431 亿美元,预计 2030 年将达到 17.6346 亿美元,复合年增长率为 14.37%。
重组细胞培养补充品是生物工程产品,旨在支持人工环境中细胞的生长、增殖和维持。这些补充品是透过重组 DNA 技术製造的,该技术将编码特定蛋白质或生长因子的 DNA 插入宿主细胞,从而产生这些所需的生物元件。其作用是优化成功培养哺乳动物、细菌和酵母细胞所需的细胞培养条件,以用于各种应用,包括治疗性蛋白质和疫苗的生产,以及在组织工程和再生医学中的应用。重组细胞培养补充品市场的主要驱动因素包括生物技术研究的进步、对生物製药的需求不断增长以及细胞培养方法在药物开发中的使用增加。此外,慢性病的全球流行正在推动新型疗法的市场开拓,进一步推动市场成长。儘管成长潜力巨大,重组细胞培养补充品市场仍面临挑战,特别是高製造成本和严格的监管要求。然而,再生医学和组织工程领域的不断扩大正在为重组细胞培养补充品市场创造重大机会。此外,干细胞治疗和基因工程研究的进步预计将为重组细胞培养补充品的应用开闢新途径,并成为市场扩张的驱动力。
主要市场统计 | |
---|---|
基准年[2023] | 6.8877 亿美元 |
预测年份 [2024] | 78431万美元 |
预测年份 [2030] | 17.6346亿美元 |
复合年增长率(%) | 14.37% |
区域洞察
由于其先进的生物技术研究环境和对生命科学的大量投资,美洲地区在重组细胞培养补充品市场呈现出强劲的成长模式。特别是,对再生医学和细胞疗法的日益重视增加了对高品质重组补充品的需求。此外,该地区是主要生物製药公司和研究机构的所在地,提高了市场参与度和创新能力。 EMEA地区呈现多元化的市场表现,其特点是欧洲成长强劲,中东影响力逐渐增强,非洲稳步推进。欧洲市场受益于大量的研究资金、成熟的製药业以及支持生物技术创新的法规环境。同时,在生命科学战略投资的推动下,中东地区对生物製药研究的兴趣日益浓厚。儘管非洲在这一领域仍在发展,但由于对生物技术和医疗基础设施的认识和投资的增加,它显示出成长潜力。在中国、日本、韩国和印度等国家快速成长的生物技术产业的推动下,亚太地区预计将在重组细胞培养补充品市场中呈现最高的成长率。该地区受益于医疗基础设施的改善、生物製药研发投资的增加以及国内外生物技术公司的伙伴关係和合作的增加。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在重组细胞培养补充品市场中的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可对重组细胞培养补充品市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该行业竞争力的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对重组细胞培养补充品市场当前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[188 Pages Report] The Recombinant Cell Culture Supplements Market size was estimated at USD 688.77 million in 2023 and expected to reach USD 784.31 million in 2024, at a CAGR 14.37% to reach USD 1,763.46 million by 2030.
Recombinant cell culture supplements are bioengineered products designed to support the growth, proliferation, and maintenance of cells in an artificial environment. These supplements are manufactured through recombinant DNA technology, which involves the insertion of DNA encoding specific proteins or growth factors into host cells, leading to the production of these desired biological elements. Their role is pivotal in optimizing the cell culture conditions necessary for the successful cultivation of mammalian, bacterial, or yeast cells for various applications, including the production of therapeutic proteins and vaccines and for use in tissue engineering and regenerative medicine. The primary drivers for the recombinant cell culture supplements market include advancements in biotechnology research, rising demand for biopharmaceuticals, and the increasing use of cell culture methods in drug development. Moreover, the rising prevalence of chronic diseases globally boosts the development of novel therapeutics, further propelling market growth. Despite the significant growth potential, the recombinant cell culture supplements market faces challenges, particularly in the form of high production costs and stringent regulatory requirements. However, the expanding field of regenerative medicine and tissue engineering presents considerable opportunities for the recombinant cell culture supplements market. Furthermore, the ongoing research in stem cell therapy and genetic engineering is expected to open new avenues for the application of recombinant cell culture supplements, thereby driving market expansion.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 688.77 million |
Estimated Year [2024] | USD 784.31 million |
Forecast Year [2030] | USD 1,763.46 million |
CAGR (%) | 14.37% |
Regional Insights
The Americas region exhibits a robust growth pattern in the recombinant cell culture supplement market owing to its advanced biotechnological research landscape and substantial investments in life sciences. The growing emphasis on regenerative medicine and cell-based therapies particularly propels the demand for high-quality, recombinant supplements. Moreover, the presence of major biopharmaceutical companies and research institutions in this region amplifies market engagement and innovation. The EMEA region displays a diverse market performance characterized by strong growth in Europe, gradually increasing influence in the Middle East and steady advancements in Africa. The European market benefits from significant research funding, a well-established pharmaceutical industry, and a regulatory environment that supports biotechnological innovations. Meanwhile, the Middle East is witnessing an emerging interest in biopharmaceutical research, fuelled by strategic investments in life sciences. Africa, though still developing in this sector, shows potential for growth with increasing awareness and investment in biotechnology and healthcare infrastructure. Asia-Pacific is projected to exhibit the highest growth rate in the recombinant cell culture supplements market, driven by rapidly growing biotech sectors in countries such as China, Japan, South Korea, and India. The region benefits from improvements in healthcare infrastructure, rising investments in biopharmaceutical R&D, and an increasing number of partnerships and collaborations involving local and international biotech firms.
Market Insights
The market dynamics represent an ever-changing landscape of the Recombinant Cell Culture Supplements Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Recombinant Cell Culture Supplements Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Recombinant Cell Culture Supplements Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Core Biogenesis and Nucleus Biologics announce strategic collaboration for manufacturing and distribution of cost effective and sustainable recombinant proteins
Nucleus Biologics collaborates with Core Biogenesis to revolutionize the availability of Good Manufacturing Practice (GMP) recombinant proteins for the industry. This partnership designates Nucleus Biologics as the GMP manufacturer and distributor of Core Biogenesis' plant-expressed recombinant human proteins, integrating these advanced proteins into Krakatoa pod-based media manufacturing systems by Nucleus Biologics and Stoic Bio. [Published On: 2024-01-24]
Albumedix and Heartseed announce Recombumin as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first in-human trial commences
Albumedix Ltd and Heartseed Inc. announced a pivotal development in cardiac therapy. Their collaboration has enabled the first human dosing of HS-001, an experimental treatment by Heartseed for advanced heart failure, utilizing Recombumin, a non-animal derived recombinant albumin, as an essential excipient. This partnership underscores Albumedix's commitment to enabling advanced therapeutic innovations, demonstrated by the strategic use of Recombumin to enhance cell viability and support cardiomyocyte sphere formation in HS-001. [Published On: 2023-03-14]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Recombinant Cell Culture Supplements Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Recombinant Cell Culture Supplements Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Becton, Dickinson and Company, Bio-Techne Corporation, BPS Bioscience, Inc., Cell Sciences, Inc., Cytiva, F. Hoffmann-La Roche Ltd., FUJIFILM Corporation, HiMedia Laboratories Pvt Ltd, InVitria, Kerry Group PLC, Kingfisher Biotech, Inc., Laurus Labs Limited, Lonza Group Ltd., Merck KGaA, Novo Nordisk A/S, Novozymes A/S, PELOBIOTECH GmbH, Repligen Corporation, Sartorius AG, STEMCELL Technologies, Takara Bio Inc., Thermo Fisher Scientific Inc., and Zhuhai Gene-Biocon Biological Technology Co., Ltd..
Market Segmentation & Coverage